Chemotherapy, a cornerstone in cancer therapy, often induces significant side effects that can compromise patient's quality of life and treatment adherence.
Proactive management involves early identification, assessment, and intervention. Implementing preemptive strategies like antiemetics for nausea and vomiting, or neuropathic agents for neuropathy, can be beneficial.
An interdisciplinary approach involving pharmacists, dietitians, psychologists, and physiotherapists can provide comprehensive care, addressing both physical and psychological aspects of side effects.
Through proactive strategies and interdisciplinary collaboration, the burden of chemotherapy side effects can be significantly reduced, enhancing patient outcomes and treatment adherence.
1.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
2.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
3.
Higher levels of HIF2α found to slow down aggressive childhood cancer
4.
PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC
5.
Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.
1.
Screening for Functional Vulnerability in Long-Term Cancer Survivorship
2.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
3.
Toxicity Surveillance for Bispecific Cancer Therapies
4.
Childhood Cancer Survivorship and Tissue Aging: Clinical Insights and Mechanistic Perspectives
5.
Practical Breakthroughs in Oncology Across Clinical Settings
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part XIV
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation